Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 680 across all filing types
Latest filing 2021-05-17 Earnings Release
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Press Release
Earnings Release Classification · 95% confidence The document is a press release announcing Gland Pharma's financial results for the fourth quarter and full fiscal year ended March 31, 2021. It includes detailed financial data such as revenue, net profit, EBITDA, margins, market-wise revenue breakdown, R&D expenses, and capex. It also mentions an upcoming earnings call to discuss these results. The presence of quarterly and full-year financial figures, along with management commentary, indicates this is a comprehensive financial report for a period shorter than a full fiscal year (quarterly and annual combined). However, since it is primarily focused on the quarterly and annual financial results announcement and includes key highlights rather than the full annual report, it fits best as an Earnings Release (ER). The document length (8754 characters) and detailed financial data support this classification rather than a brief announcement or a full annual report (10-K). FY 2021
2021-05-17 English
Financial Result Updates
Annual Report Classification · 95% confidence The document is a detailed communication from Gland Pharma Limited to stock exchanges regarding the outcome of a Board Meeting held on May 17, 2021. It includes approval of audited financial results (standalone and consolidated) for the quarter and financial year ended March 31, 2021, along with the Audit Report. The document contains the full Independent Auditor's Report on the consolidated financial results, including the auditor's opinion, basis for opinion, management responsibilities, and auditor responsibilities. The presence of comprehensive audited financial statements and the audit report for the full fiscal year indicates this is a full annual financial report. The document also mentions the Annual General Meeting date and director appointments, but the primary content is the audited financial results and audit report for the fiscal year ending March 31, 2021. Therefore, this document fits the definition of an Annual Report (10-K equivalent). It is not merely an announcement or a brief summary but contains substantive financial data and audit opinions. FY 2021
2021-05-17 English
Outcome of Board Meeting
Annual Report Classification · 95% confidence The document is a detailed communication from Gland Pharma Limited to stock exchanges regarding the outcome of a Board Meeting held on May 17, 2021. It includes approval of audited financial results (standalone and consolidated) for the quarter and financial year ended March 31, 2021, along with the Audit Report. The document contains the full Independent Auditor's Report on the consolidated financial results, including the auditor's opinion, basis for opinion, management responsibilities, auditor responsibilities, and other matters. The presence of comprehensive audit details and financial results for a full fiscal year indicates this is a full annual financial report. The document also mentions the Annual General Meeting date and director appointments, but the primary content is the audited financial results and audit report for the fiscal year ended March 31, 2021. This matches the definition of an Annual Report (10-K) filing, which covers the company's full financial performance for the year. The document length (15,000 characters) and detailed financial data confirm it is not merely an announcement or summary. Therefore, the appropriate classification is Annual Report (10-K). FY 2021
2021-05-17 English
Monitoring Agency Report
Capital/Financing Update Classification · 95% confidence The document is titled 'Report of the Monitoring Agency for the Quarter ending March 31, 2021' and references SEBI regulations related to the monitoring of IPO proceeds. It is a detailed report from the monitoring agency (Axis Bank Limited) on the utilization of IPO proceeds for the quarter ended March 31, 2021. The content includes financial details about the use of funds raised through the IPO, progress on the objects of the issue, and compliance with regulatory requirements. This type of report is a regulatory compliance document related to capital raised and its utilization, which fits the category of Capital/Financing Update (CAP). It is not an annual or interim financial report, nor an earnings release or audit report. It is a specific monitoring report on capital utilization as required by SEBI regulations.
2021-05-12 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 95% confidence The document is a notification about the allotment of equity shares following the exercise of Employee Stock Options (ESOP). It mentions the increase in the company's issued share capital and is addressed to stock exchanges as per SEBI regulations. The content is an announcement of a capital change, specifically related to share allotment and capital structure update. The document length is short (1584 characters) and does not contain financial statements or detailed financial data. Therefore, it is not a full financial report but an announcement of a capital change event.
2021-05-05 English
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 95% confidence The document contains multiple declarations and disclosures under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, specifically referencing regulation 31(4) and regulations 30(1) and 30(2). It details shareholding information of promoters and persons acting in concert, including the number and percentage of shares held. The document is a formal regulatory disclosure about shareholding and encumbrance status, not a financial report, earnings release, or management discussion. It is not an announcement of voting results or a proxy solicitation. The content fits the definition of a Major Shareholding Notification (MRQ), which involves notification of changes or status in significant share ownership levels. The document length is substantial and contains detailed shareholding data, confirming it is not a brief announcement or a report publication notice. Therefore, the appropriate classification is MRQ with high confidence.
2021-04-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.